# Bluebird Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bluebird-bio

- Industry: Pharmaceuticals
- Headquarters: Somerville, US
- Website: www.bluebirdbio.com
- Total disclosed funding: $125M
- Latest round: Series D (Jul 24, 2012)
- Investors on record: 9

## About

Founded in 1993 and based in Massachusetts, US, Bluebird Bio, Inc. operates as a biotechnology company that develops and provides gene therapy, cancer immunotherapy, and gene editing platforms to cure patients with genetic and rare diseases.

## Funding rounds

- Series D, Jul 24, 2012, $60M — ARCH Venture Partners, TVM Capital Life Science, Healthcare Royalty Partners, Forbion, Deerfield Capital Management, Third Rock Ventures, RA Capital Management
- Series C, Apr 20, 2011, $30M — ARCH Venture Partners, TVM Capital Life Science, Easton Capital Investment Group, Forbion, Third Rock Ventures
- Series B, Mar 12, 2010, $35M — TVM Capital Life Science, Easton Capital Investment Group, Forbion, Third Rock Ventures, Sanofi Ventures

## Investors

- TVM Capital Life Science (https://capitalatlas.ai/funds/tvm-capital-life-science) — Series B, Series C, Series D
- Easton Capital Investment Group (https://capitalatlas.ai/funds/easton-capital-investment-group) — Series B, Series C
- Forbion (https://capitalatlas.ai/funds/forbion) — Series B, Series C, Series D
- Third Rock Ventures (https://capitalatlas.ai/funds/third-rock-ventures) — Series B, Series C, Series D
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series B
- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series C, Series D
- Healthcare Royalty Partners (https://capitalatlas.ai/funds/healthcare-royalty-partners) — Series D
- Deerfield Capital Management (https://capitalatlas.ai/funds/deerfield-capital-management) — Series D
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series D